Last edition
News about "BerGenBio "
BerGenBio Partners with Tempus to Accelerate Development in STK11m Non-Small Cell Lung Cancer
BerGenBio's on-going BGBC016 Phase 1b/2a trial is designed to assess the benefit of adding bemcentinib to the current standard of care treatment (immunotherapy + doublet chemotherapy) in 1L STK11m patients, a population with poor outcomes and no specific therapies today.
BerGenBio | 21/08/2024 | By Aishwarya
BerGenBio Begins Phase 2a in First Line NSCLC Patients with STK11m
BerGenBio ASA has initiated Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non-Small Cell Lung Cancer (NSCLC) patients
BerGenBio | 21/03/2024 | By Manvi | 197
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy